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The development of cardiovascular disease during renal impairment involves striking
multi-tiered, multi-dimensional complex alterations encompassing the entire oxygen
transport system. Complex interactions between target organ systems involving
alterations of the heart, vascular, musculoskeletal and respiratory systems occur
in Chronic Kidney Disease (CKD) and collectively contribute to impairment of
cardiovascular function. These systemic changes have challenged our diagnostic and
therapeutic efforts, particularly given that imaging cardiac structure at rest, rather than
ascertainment under the stress of exercise, may not accurately reflect the risk of
premature death in CKD. The multi-systemic nature of cardiovascular disease in CKD
patients provides strong rationale for an integrated approach to the assessment of
cardiovascular alterations in this population. State-of-the-art cardiopulmonary exercise
testing (CPET) is a powerful, dynamic technology that enables the global assessment of
cardiovascular functional alterations and reflects the integrative exercise response and
complex machinery that form the oxygen transport system. CPET provides a wealth of
data from a single assessment with mechanistic, physiological and prognostic utility. It is
an underutilized technology in the care of patients with kidney disease with the potential
to help advance the field of cardio-nephrology. This article reviews the integrative
physiology and pathophysiology of cardio-renal impairment, critical new insights derived
from CPET technology, and contemporary evidence for potential applications of CPET
technology in patients with kidney disease.
Keywords: cardiopulmonary exercise testing (CPET), cardiovascular functional capacity, VO2Peak, chronic
kidney disease (CKD), end-stage kidney disease (ESKD), dialysis
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INTRODUCTION
Cardiovascular disease is a modern-day global epidemic (Kwan
and Benjamin, 2015). Over the past century, our world has
witnessed a striking epidemiologic transition in the predominant
cause of death, from communicable diseases and nutritional
deficiencies to non-communicable diseases (Nascimento et al.,
2014). At the forefront of non-communicable conditions are
diseases of the cardiovascular system. A number of models
that include health behaviors, population aging, and increasing
rates of urbanization and globalization that increase the
burden of cardiovascular risk factors, partially account for
this epidemiologic transition in cardiovascular disease (CVD)
(Yusuf et al., 2001). Other well-established risk factors for CVD
include hyperlipidemia, hypertension, smoking and diabetes.
However, in recent years, Chronic Kidney Disease (CKD) has
emerged as a risk factor of considerable importance (Sarnak
et al., 2003). In fact, CVD is now well-recognized to be
the leading cause of death in CKD patients. Individuals with
only mild decrements in glomerular filtration rate (GFR) to
<60 ml/min/1.73 m2 have already a two-fold increased risk
of cardiovascular mortality and this risk increases up to 20-
fold by the time a patient needs renal replacement therapy,
or end-stage kidney disease (ESKD) (Gansevoort et al., 2013).
The pattern of overt CVD in CKD patients differs substantially
from the general population. Occlusive coronary artery disease
(CAD) accounts for only a minority of cardiovascular deaths
in advanced CKD, with the majority being attributed to sudden
cardiac death (SCD) and congestive heart failure, in contrast to
the general population [Wilson et al., 2001; Wayhs et al., 2002;
US Renal Data System (USRDS), 2013].
As members of the scientific and health care community,
we are challenged with an ethical and moral obligation to help
reduce premature mortality from CVD in our growing CKD
population. However, the challenge of helping to improve
patient outcomes in this population is compounded by the
highly complex processes involved in CVD development
as kidney failure ensues. As renal function declines, the
development of CVD involves both traditional and non-
traditional risk factors such as uremia, pro-inflammatory
cytokines, volume overload, mineral disorders, electrolyte
disturbances, anemia, sympathetic nerve activation, renin-
angiotensin-aldosterone (RAAS) activation and vitamin
D deficiency. Additionally, emerging risk factors such as
elevated fibroblast growth factor (FGF)-23, low Klotho
levels, post-translational protein modifications, and gut
derived uremic toxins have now been tightly linked with
CVD development in CKD (Rhee and Gerszten, 2012; Kahn
et al., 2013; Verbrugge et al., 2015) (Figure 1). Central to
these processes are complex interactions between multiple
target organ systems that include the renal, musculoskeletal,
pulmonary, gastrointestinal, vascular, and cardiovascular
systems. Interactions between these organ systems underlie
critical homeostatic processes such as endocrine loops that
tightly regulate mineral metabolism and other organ cross-talk.
Their collective failure originates from kidney dysfunction
and contributes to overall cardiovascular impairment (Ting
et al., 2015; Lim et al., 2020). These organ system interactions,
therefore, provide strong rationale for an integrated physiologic
approach to assessing cardiovascular changes in CKD.
The striking multi-tiered, multi-dimensional complexities of
CVD development in CKD have challenged our diagnostic
and therapeutic efforts. For example, imaging of single
organs such as the heart by echocardiography or MRI does
not adequately reflect the complex systemic processes that
lead to cardiovascular impairment in CKD and is therefore
insufficiently sensitive to accurately reflect cardiovascular
health in this population. Despite huge scientific, economic
and financial investment, many of our cardio-renal outcome
trials in nephrology have yielded neutral results and have
not demonstrated a treatment benefit (Lim et al., 2018).
This may be secondary to multiple reasons such as patient
heterogeneity, complexity of cardio-renal pathophysiology,
competing risks and importantly, limitations of resting cardiac
geometric endpoints for tracking disease improvement or
decline in the CKD population. As a result, clinicians
are left with potentially equivocal recommendations and
patients are left without evidence-based guidance to manage
their condition. This state of the union therefore demands
alternative or novel approaches to investigative, diagnostic
and therapeutic efforts to help combat the burden of
cardiovascular disease in CKD.
The emergence of state-of-the-art Cardiopulmonary Exercise
Testing (CPET) technology and its application to cardiovascular
disease research in nephrology is one such alternative approach
gaining significant traction. While only a handful of studies
have applied CPET technology to study patients with CKD,
these studies have already revealed significant mechanistic and
physiological insights, and have provided evidence to support
the potential use of CPET-derived indices in a variety of
applications in nephrology. This article considers integrative
physiological and pathophysiological insights into cardiovascular
impairment in CKD derived from CPET technology, and
appraises contemporary evidence for the potential application of
CPET to help advance the field of cardio-nephrology.
INTEGRATIVE PHYSIOLOGY AND THE
FICK PRINCIPLE
The Fick Principle and the Fick Equation
As CKD progresses, the integrated metabolic machinery required
for the cardiovascular system to function and enable optimal
exercise performance is impaired. At the level of the heart and
vasculature, kidney failure leads to a uremic phenotype that
recapitulates many features of cardiovascular aging, including
myocyte hypertrophy, reduced myocardial capillarization and
non-vascularized myocardial interstitial fibrosis and calcification
as well as vascular calcification, arteriosclerosis and arterial
stiffening of systemic vasculature (Aoki et al., 2005; Edwards
et al., 2014). The molecular, ultrastructural and geometric
changes of the heart and vasculature collectively lead to
reduced cardiac efficiency and hence increased myocardial energy
expenditure and oxygen consumption. Unfortunately, cardiac
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FIGURE 1 | Traditional and novel risk factors for development of cardiovascular disease and the cardio-renal phenotype in CKD.
remodeling occurs early in the course of CKD leading to left
ventricular (LV) diastolic then systolic dysfunction and sudden
cardiac death (Edwards et al., 2014; Rutherford and Mark, 2017).
Critically, CKD results in the failure of multiple organ systems
beyond alterations to the heart and vasculature (Figure 2)
(Walsh, 1997; Wasserman, 1997; Moorthi and Avin, 2017;
Lim et al., 2018): The musculoskeletal system is subject to
impairment as CKD progresses resulting in biomechanical
failure. This involves muscle wasting (sarcopenia) and alterations
in bone mineral metabolism occur leading to widespread
consequences, including increased risk of bone mineral disorders
(BMD), falls and frailty, hospitalizations, and poorer quality
of life (Moorthi and Avin, 2017). Significant interactions
between the kidneys and the lungs are also well-known.
For example, pulmonary-renal syndromes due to small-vessel
vasculitis can cause significant renal impairment, including
rapidly progressive glomerulonephritis (RPGN) and pulmonary
hemorrhage. Diabetes can cause diabetic nephropathy as well
as impaired lung function, involving decreased lung diffusion
capacity and increased risk for pulmonary hypertension (Sorino
et al., 2019). Additionally, the development of restrictive lung
disease has been associated with progressive CKD (Mukai
et al., 2018). Underlying these systemic target organ changes
are widespread ultrastructural and molecular alterations that
contribute to subclinical disease early in the course of
CKD and may not be readily detected with conventional
resting imaging studies (Ting et al., 2015; Kim et al., 2018;
McGregor et al., 2018).
These diverse systemic alterations contribute to the
impairment of the cardiovascular system to fulfill its primary
function, that is, to be an effective oxygen transport system
(Dunn et al., 2016). The role of the many individual components
of the cardiovascular system to function effectively in oxygen
transport is defined by the Fick Principle. This principle was first
described by the German physiologist, Adolf Fick in 1870 and for
over 150 years has remained one of the most solid fundamental
principles of human cardiovascular physiology (Albouaini et al.,
2007). The Fick principle (mathematically expressed by the
Fick equation) states that oxygen uptake (VO2) equals cardiac
output multiplied by the arterial minus venous oxygen content,
as illustrated in Figure 2.
The resting oxygen uptake of a healthy individual in a
sitting position approximately equals 3.5 ml/min−1/kg−1 or
one metabolic equivalent (MET). However, it has now become
clear that resting cardiac and pulmonary function testing cannot
reliably predict exercise performance and functional capacity,
and that overall health status is more strongly associated with
exercise tolerance than with resting measurements (Albouaini
et al., 2007). This understanding, together with the principle that
the fundamental role of the cardiovascular system is to function
as an effective oxygen transport system, provides the rationale
for the assessment of oxygen uptake (VO2) at maximal or
peak exercise (VO2Peak) as a robust, objective and reproducible
index of cardiovascular functional capacity. While the definition
of VO2Max and VO2Peak are different and will be discussed
in further detail below, for the purposes of this article we
will use the term VO2Peak (unless where VO2Max has been
explicitly referred too in an original article). VO2Peak reflects
the maximal ability of an individual to take in, transport and use
oxygen and defines the individual’s functional aerobic capacity
(Mezzani, 2017).
Applying the Fick Principle to Patients
With CKD
Understanding the Fick equation is of critical importance in
order to appreciate how progressive CKD alters cardiovascular
function in this population, and thus the utility of functional
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FIGURE 2 | The Fick equation and the coupling of external and cellular respiration. The three interlinked gears represent the functional interdependence between the
lungs, circulation and muscle. This facilitates O2 transport from the lungs to the mitochondria and, in reverse, CO2 from the muscle to the lungs (adapted from
Wasserman, 1997). The detrimental multisystemic effects of kidney disease on this integrated physiological process are indicated. V˙O2, oxygen uptake; V˙CO2,
carbon dioxide output; prod, production; consum, consumption; SV, stroke volume; HR, heart rate; CaO2, arterial O2 content; CaO2, venous O2 content; LVH, left
ventricular hypertrophy.
testing. Lessons learned from the Fick equation, as applied
to the complex systemic changes that occur with declining
kidney function, demand that we look beyond cardiac or
vascular changes alone, toward an integrative viewpoint when
assessing overall cardiovascular health status in CKD patients
rather than static single-organ measures. For example, left
ventricular hypertrophy (LVH) is highly prevalent in the
dialysis population and is associated with high rates of all-
cause and cardiovascular mortality (Silberberg et al., 1989;
Foley et al., 1995; London, 2002). However, not all incident
dialysis patients have LVH; in fact, approximately 20% do
not. Furthermore, a small proportion of dialysis patients
experience some regression, and daily dialysis compared to
thrice weekly can prevent worsened LVH (Group et al.,
2010). Still, dialysis patients who do not have LVH or exhibit
regression continue to have elevated risk of cardiovascular
mortality (Charytan, 2014). Similarly, kidney transplantation
is associated with improved cardiovascular survival (Meier-
Kriesche et al., 2004); however, serial cardiac magnetic resonance
(CMR) imaging which provides accurate and reproducible
assessment of cardiac dimensions, has failed to identify
significant regression in LV mass after transplantation (Patel
et al., 2008). Taken together, these clinical observations
therefore suggest that measures of LV geometry may not
accurately reflect the risk of premature cardiovascular death
in advanced CKD.
Importantly, an alteration of any of the four variables in the
Fick equation that determines VO2 peak can occur in CKD. As
an example, in advanced CKD patients, a reduction in maximal
heart rate or a blunted chronotropic response occurs, leading to
reduced cardiac output (Ting et al., 2015). These maladaptive
processes coupled with widespread arterial calcification and
stiffening that contribute to increased afterload, lead to further
reductions in cardiac output (Ferro et al., 2012). Impairment
of the musculoskeletal system from sarcopenia with muscle
mitochondrial dysfunction and progressive anemia are common
complications of advanced CKD, can also have profound effects
on maximal arterial minus mixed venous oxygen content (Cao2 –
Cvo2max) (Lim et al., 2020). All pathophysiological states
that impair oxygen transport from air to mitochondria, and
oxygen use during exercise can contribute to cardiovascular
dysfunction and reduced cardiovascular functional capacity. This
makes the assessment of VO2Peak and other cardiovascular
functional variables particularly powerful measures for assessing
cardiovascular health. Reduction in VO2Peak has been observed
not only in several different organ or systemic conditions (such
as chronic heart failure and chronic obstructive pulmonary
disease), or conditions that affect the musculoskeletal system
(such as mitochondrial myopathies and amyotrophic lateral
sclerosis) and are too numerous to completely list here,
but have also been described in bed-rest and deconditioning
(Mezzani, 2017).
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CARDIOPULMONARY EXERCISE
TESTING (CPET)
Cardiopulmonary exercise testing is a powerful, dynamic
technology that incorporates ventilatory gas exchange
measurements during graded exercise. CPET assesses gas
exchange measures of O2uptake (VO2), carbon dioxide output
(VCO2) and minute ventilation (VE) and some CPET systems,
can provide breath-by-breath analysis of these variables.
These measures are used to derive various other gas exchange
patterns and can provide organ-specific information on the
dysregulated responses to exercise. In the general heart failure
population, CPET-derived indices have been recognized as
robust markers for the assessment of cardiovascular disease
compared to conventional resting imaging for several reasons.
Firstly, the coupling of morphological cardiac alterations to
cardiovascular performance is largely unknown; secondly,
resting cardiopulmonary imaging tests cannot reliably predict
functional performance; and thirdly, there is increasing
appreciation that overall health status correlates better with
exercise tolerance (American Thoracic Society and American
College of Chest Physicians, 2003). Here, we will provide a brief
discussion of major CPET variables and a summary of commonly
derived CPET data is provided in Table 1.
Oxygen Uptake and Peak Oxygen Uptake
Maximum oxygen uptake (VO2Max) is defined as the highest
rate of oxygen uptake during intense, maximal exercise whereby
no further increases in work rate can cause additional rises
in VO2 (i.e., plateau) (Bassett and Howley, 2000). Peak VO2
(VO2Peak) is directly reflective of VO2Max and is defined
as the highest value of VO2 obtained upon an incremental
or other high-intensity exercise test that brings the individual
to the limit of tolerance (Whipp and Ward, 1990). VO2Peak
considers the integrative exercise response involving the degree
of ventricular function (pumping capacity), oxygen transport in
blood (O2 carrying capacity), pulmonary and vascular function
(O2 delivery), skeletal muscle metabolic capacity (O2 utilization),
and as well as ultrastructural and molecular changes of organ
systems involved, and their interactions (Malhotra et al., 2016).
During incremental exercise testing, it is defined as the highest
volume of VO2 averaged over a period of time 20- to 30- s
period achieved at presumed maximal effort (Figure 3). The
period of which VO2Peak is measured isn’t standardized, but
generally range between a 20- to 30- s period to a minute
depending on investigator preference. VO2Peak is quantified in
liters or milliliters of oxygen per minute or in milliliters per
kilogram of body weight per minute. It is a parameter that
describes the maximal amount of energy obtainable by aerobic
metabolism per unit time (aerobic power) at peak or incremental
exercise (Mezzani, 2017). It is therefore powerfully reflective of
cardiovascular functional capacity by taking into consideration
maximal exercise tolerance.
On average, VO2Peak declines by 10% per decade after the
age of 30 and this has been attributed to decreasing maximal
heart rate, stroke volume, blood flow to skeletal muscle and
skeletal muscle aerobic potential (Betik and Hepple, 2008). Due
to higher hemoglobin levels, greater muscle mass and stroke
volume, VO2Peak is approximately 10–20% greater in men than
in women of comparable age (Astrand, 1960). Because VO2Peak
is influenced by age, gender, and muscle mass, it is therefore
appropriate to interpret VO2Peak normalized to age, gender and
weight-based normative values (Grassi et al., 2009).
Submaximal Oxygen Uptake
Measurements
Although VO2Peak has been the most commonly used variable
for assessing cardiovascular functional capacity, gas exchange
indices obtainable during submaximal exercise have emerged
and may rival or even exceed the prognostic utility of VO2Peak
in various settings (Malhotra et al., 2016). Incremental exercise
can be divided into two phases, firstly an initial phase that lasts
until 50–60% of VO2Peak during which expired ventilation (VE)
increasing linearly with VO2 and VCO2. This is followed by
a second phase during which VE increases disproportionately
relative to first VO2 and then VCO2 (Albouaini et al., 2007).
This transition point was initially termed the anaerobic threshold
(AT), because in healthy subjects it tends to coincide with the
exercise intensity at which the rates of glycolysis and especially
glycogenolysis accelerate rapidly, leading to accumulation of
pyruvate and hence lactate in muscle and blood (i.e., the lactate
threshold). It has long been known, however, the muscle is only
truly anaerobic at intensities > 100% of VO2max. Furthermore,
numerous studies have demonstrated that it is possible to
dissociate changes in VE from changes in lactate (Poole and
Gaesser, 1985; McLellan and Gass, 1989). For example, the
muscles of patients with McArdle’s disease lack the ability to
produce lactate due to the absence of glycogen phosphorylase
activity. Such individuals therefore do not exhibit a lactate
threshold, but their VE increases non-linearly with exercise
intensity similar to that of a normal person (Hagberg et al.,
1990). Similarly, high or low muscle glycogen levels, high or low
pedaling rates, different types of exercise training, etc., have all
been shown to dissociate changes in VE from changes in lactate
(Hughes et al., 1982). The “breakpoint” in VE with increasing
exercise intensity is therefore more appropriately described as
simply a ventilatory threshold (VT), and can be estimated
non-invasively using various quantitative methods, such as the
V-slope method. In the V-slope method, VT is defined as the VO2
at which the rate of increase in VCO2 relative to VO2 increases in
the absence of hyperventilation (Beaver et al., 1986). Although
estimation of VT can be replaced by direct blood sampling to
determine the lactate threshold (LT), this is rarely performed in a
clinical setting.
Submaximal CPET indices such as VT are attractive due to
the relative ease with which they are ascertained during low-
level exercise, their independence from volitional effort, and
their relevance to an individual’s ability to perform activities
of daily living. Ascertainment of submaximal VO2 parameters
becomes particularly relevant in patients with heart failure
who fail to fulfill the criteria for maximum volitional effort,
and this is discussed in more detail below. For example, the
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TABLE 1 | Summary of CPET variables and description.
Abbreviation Parameter Units Description
WR Work rate Watts (W) Work per unit time (where work represents the movement resulting from force
being exerted against a mass, e.g., cycle ergometry).
RPE Rating of perceived exertion Self-reported subjective measure of the sensations of exertion being
experienced by the participant.
t Endurance time s Total exercise time (excluding warm-up).
HR Heat rate min−1 Number of heart beats (cardiac cycles) per minute.
HRR Heart rate reserve min−1 Difference between the predicted maximal heart rate and actual peak heart rate
achieved.
SBP Systolic blood pressure mmHg
DBP Diastolic blood pressure mmHg
RPP Rate pressure product – Product of HR and SBP. Indirect measure of myocardial work.
FEV1 Forced expiratory volume in one
second
l Volume of air expelled from the lungs during first second of forced expiration
(measured at rest).
FVC Forced vital capacity l Maximal volume of air expelled from the lungs after maximal inspiration
(measured at rest).
BF Breathing frequency min−1 Number of breaths (ventilatory cycles) per minute.
VT Tidal volume l Volume of air inhaled or exhaled in a single breath.
V˙E Minute ventilation l.min−1 Volume of air inhaled or exhaled per minute.
MVV Maximum voluntary ventilation l.min−1 Maximal ventilatory ability measured by repeated maximal inspiration and
expiration over a given time period, e.g., 10 s).
BR Breathing reserve % Difference between resting MVV and maximal VE during exercise. Represents
remaining capacity to increase ventilation at maximal exercise.
V˙O2 Oxygen uptake ml.min−1
ml.kg−1.min−1
Volume of O2 uptake per minute measured in expired air.
V˙O2 max Oxygen uptake at maximal exercise ml.min−1
ml.kg−1.min−1
Highest O2 uptake achievable during incremental exercise.
V˙O2 peak Oxygen uptake at peak exercise ml.min−1
ml.kg−1.min−1
Highest O2 uptake achievable during incremental exercise in the context of any
physiological limitation (often used synonymously with V˙O2max ).
V˙O2 % pred Oxygen uptake as a percentage of
predicted
% Highest O2 uptake achieved during incremental exercise relative to predicted
value (values of 80–120% predicted are considered normal).
V˙CO2 Carbon dioxide output ml.min−1 Volume of CO2 exhaled per minute measured in expired air.
RER Respiratory exchange ratio – Ratio of CO2 output to O2 uptake measured in expired gas.
VAT Ventilatory anaerobic threshold ml.kg−1.min−1 O2 uptake at the ventilatory anaerobic threshold.
VAT % pred.
V˙O2peak
Ventilatory anaerobic threshold as a
percentage of predicted V˙O2 peak
% Oxygen uptake at the ventilatory anaerobic threshold relative to predicted
V˙O2peak . Values below 40% are generally considered indicative of pathology.
PETO2 End tidal partial pressure of O2 mmHg Partial pressure (tension) of O2 in exhaled gas at the end of expiration
PETCO2 End tidal partial pressure of CO2 mmHg Partial pressure (tension) of CO2 in exhaled gas at the end of expiration
O2 pulse Oxygen pulse ml Amount of O2 extracted by tissue per heart beat (i.e., stroke volume) Measure
of overall cardiovascular efficiency.
OUES Oxygen uptake efficiency slope – Regression-derived variable representing the relationship between
log-transformed VE and V˙O2. Measure of overall cardio-pulmonary function.
1V˙O2/1WR slope Oxygen uptake/work slope – Increase in O2 uptake in relation to a simultaneous increase in work rate. Lower
values indicate inability to augment V˙O2 in response to increase in WR.
V˙E/V˙O2 Ventilatory equivalent for O2 – Volume of O2 uptake per unit of ventilation.
V˙E/V˙CO2 Ventilatory equivalent for CO2 – Volume of CO2 output per unit of ventilation.
V˙E/V˙CO2 slope Slope of the ventilatory response – The slope of the response of the ventilatory equivalent for CO2. Measure of
ventilatory efficiency (ventilation/perfusion matching).
Sao2 Oxyhemoglobin saturation % Oxyhemoglobin saturation measured by pulse oximetery
ability to exercise beyond the VT can help distinguish impaired
cardiovascular functional capacity from non-cardiac (pulmonary
or musculoskeletal) causes of exercise limitation (Albouaini et al.,
2007). However, this is not universally true as patients with mitral
stenosis for example, often stop exercising before they reach
VT, while patients with chronic obstructive pulmonary disease
(COPD) commonly pass the VT.
Respiratory Exchange Ratio
The respiratory exchange ratio or RER is the ratio between VCO2
and VO2. During steady-state exercise below VT, RER provides
an indication of substrate selection (i.e., fat vs. carbohydrate).
Above VT, however, progressive increases in VE result in the
liberation of “excess” CO2 from bicarbonate stores. This helps
to buffer the protons being produced as a result of high rates
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FIGURE 3 | Breath-by-breath gas exchange measurements during a ramp protocol CPET. (A) Demonstrates the linear increase in V˙O2 in response to a linear
increase in work rate. Achievement of V˙O2Peak is confirmed by the plateau in V˙O2 beginning at approximately 125 W. (B) Displays the derivation of the VAT using
the ‘V-slope’ method. The point at which the lower (blue) and upper (red) slopes intersect indicates the VAT. V˙O2, oxygen uptake; V˙CO2, carbon dioxide output; VAT,
ventilatory anaerobic threshold.
of glycolysis/glycogenolysis, but invalidates the use of RER as a
measure of substrate oxidation. Nonetheless, RER still provides
an objective descriptor of subject motivation. An RER greater
than approximately 1.0 implies that an individual has attained
a maximal volitional effort, whereas an RER less than this value
suggests that they have not. Measurement of RER during CPET
testing and is therefore of crucial significance to assist in the
attainment of reliable and clinically meaningful VO2Peak values
(Mezzani, 2017).
Oxygen Pulse
Oxygen pulse is the ratio between VO2 and heart rate, and reflects
the amount of oxygen consumed per heartbeat. It is a measure for
stroke volume and peripheral oxygen extraction during exercise,
and can be calculated as stroke volume multiplied by C(a-v)O2
(Mezzani, 2017). Flattening or downward displacement of oxygen
pulse kinetics during incremental exercise has been shown to be
reflective of peripheral vascular perfusion or extraction or central
cardiogenic performance limitations (Mezzani, 2017). Under
certain conditions, the morphological analysis of its curve can aid
in the diagnosis of ventricular dysfunction and exercise-induced
myocardial ischemia (Herdy et al., 2016).
CARDIOVASCULAR FUNCTIONAL
CHANGES IN CKD
End-Stage Kidney Disease (ESKD)
In a matched cohort study, Ting et al. (2015) examined
cardiovascular functional capacity changes in a study that
recruited 80 dialysis patients and 80 hypertensive controls.
The authors reported that dialysis patients had a reduction
in VO2Peak (18 ± 4.1 ml/min−1/kg−1) compared to controls
(24.5 ± 7.1 ml/min−1/kg−1, p < 0.001) (Ting et al., 2015). The
study also found that LV ejection fraction was significantly lower
in dialysis patients compared to hypertensive controls, however,
this was not predictive of VO2Peak. Further analysis revealed
that LV filling pressure and pulse wave velocity were independent
predictors of reduced VO2Peak in dialysis patients. Conversely,
LV mass index and LV end-diastolic volume were predictive
of VO2Peak in the hypertensive control group. These results
suggest important mechanistic differences leading to reduced
cardiovascular function in advanced CKD as opposed to those
in hypertensive cardiovascular disease alone. The finding that
LV ejection was not predictive of VO2Peak is not surprising,
given that the majority of CKD patients with heart failure have
diastolic rather than systolic dysfunction (Loutradis et al., 2018).
It is possible that increased LV diastolic stiffness may in part
contribute to impaired cardiovascular functional capacity as
CKD progresses; further studies are required to elucidate this.
Although myocardial growth and remodeling may be a dynamic,
adaptive process that occurs early in the course of CKD, it is
likely that sustained cardiac afterloads due to volume overload in
ESKD is a major contributor to progressive cardiac remodeling.
Additionally, in the study by Ting et al. (2015) dialysis patients
exhibited chronotropic incompetence with a reduced maximal
heart rate. Taken together, these results suggest that maladaptive
LV changes and blunted chronotropic responses are involved in
impairment of cardiovascular function in dialysis patients.
The CAPER (Cardiopulmonary Exercise Testing in Renal
Failure and After Kidney Transplantation) study by Lim
et al. (2020) was the first study to assess cardiovascular
functional changes using CPET before and after kidney
transplantation. CAPER was a prospective, non-randomized,
single-center, 3-arm controlled cohort study that recruited a
total of 253 patients: 81 stage 5 CKD patients who underwent
kidney transplantation, 85 non-transplanted waitlisted stage
5 CKD patients, and 87 hypertensive controls. All patients
underwent CPET and echocardiography assessment at baseline
and were followed longitudinally for up to 1 year. In the
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non-transplanted CKD stage 5 group, who were waitlisted but
did not undergo transplantation after 1 year follow-up, CPET
was sensitive enough to detect a decline in cardiovascular
functional capacity (as assessed by VO2Peak) (18.9 ± 4.7 to
17.7 ± 4.1 mL.min−1.kg−1, p < 0.001). These results become
even more revealing considering that the study found that
LV mass index did not change (p = 0.20). This highlights the
limitations of using LV mass or hypertrophy as a surrogate
endpoint for tracking disease progression in advanced CKD
patients, and that other processes beyond LV geometric indices
are likely involved in driving overall cardiovascular functional
decline in this population.
CAPER found that LV ejection fraction declined after
1 year (p = 0.003). Among the variables that were correlated
with VO2Peak changes from baseline to 12 months in the
non-transplanted dialysis group, were LV mass index, LV ejection
fraction, and maximal heart rate as well as hemoglobin level
(anemia). It is currently unknown how cardiovascular functional
capacity alters with increasing dialysis vintage (length of time on
dialysis) beyond 1 year and this data will be critical to help inform
cardiovascular risk. Additionally, it is unknown how processes
such as myocardial remodeling through fibrosis, myocardial
arteriole calcification, capillary rarefaction, myocardial stunning
and complex circulating factors such as FGF23, Klotho and
metabolites modulate VO2Peak decline in dialysis. We postulate
that these factors may contribute to reduced cardiac compliance
and ventricular contractility, loss of arterial elasticity, as well
as end-organ damage of the lungs and skeletal muscle system.
Further studies are needed to evaluate this.
Data from the CAPER study highlight the complex organ
system interactions that are involved in regulating cardiovascular
function in advanced CKD patients and provide evidence of the
contribution of multiple target organs that collectively regulate
the oxygen transport system (Figure 2). Given that CKD severity
is associated with restrictive lung disease (Mukai et al., 2018)
and that the lungs are an integral part of the oxygen transport
system, it is worrying that few studies have comprehensively
assessed pulmonary function changes with advancing CKD, and
no studies have examined its relative contribution to impaired
cardiovascular functional capacity in CKD. Studies that couple
CPET with advanced imaging techniques such as Magnetic
Resonance Imaging will help to better elucidate background lung,
cardiac and arterial changes that occur and their contribution to
impaired cardiovascular functional capacity in this population.
Additionally, given that sarcopenia is a feature of advanced
CKD, we are in need of further studies to evaluate the relationship
between direct measures of skeletal muscle contractile function
and segmental lean muscle mass with changes in cardiovascular
functional capacity. Of note, exercise intolerance is an important
comorbidity in patients with advanced CKD and is associated
with arterial stiffening and endothelial dysfunction (Downey
et al., 2017). Emerging data has suggested that reduced
cardiovascular functional capacity may be improved with
exercise training. In a pilot randomized clinical trial, McGregor
et al. (2018) demonstrated parallel improvements in isometric
quadriceps strength and exercise cardiovascular functional
capacity without significant changes in resting echocardiographic
cardiac morphologies, following 10-weeks of exercise training
among dialysis patients in a randomized, assessor-blinded,
controlled study.
CPET has raised many other questions, for example, how
cardiovascular functional capacity changes during short and
long interdialytic periods, and how the effects of conventional
thrice weekly hemodialysis versus intensive hemodialysis and
peritoneal dialysis may alter cardiovascular functional capacity.
Further studies are needed.
Kidney Transplant Recipients
In the CAPER study, Lim et al. (2020) reported significantly
improved cardiovascular functional capacity as assessed
by VO2Peak in the kidney transplant group 1 year after
transplantation (20.7 ± 5.8 to 22.5 ± 6.3 mL.min−1.kg−1,
p < 0.001). However, cardiovascular functional capacity
was not restored to the level observed in the control group
without CKD, and this was consistent with the incomplete
normalization of kidney function with transplantation (mean
eGFR 59.1± 18.4 mL.min−1.1.73 m−2, to the level of CKD stage
3). These findings become all the more meaningful considering
that LVMI did not change after kidney transplantation, despite
a significant improvement in VO2Peak and when contrasted
with the inverse direction of change in non-transplanted
dialysis patients. Despite unaltered LVMI, the study reported an
improvement in LVEF in the transplanted group at 12 months.
These latter findings are consistent with a recent study using
volume-independent cardiac magnetic imaging that failed to
show significant change in LVMI and LVEF after transplantation
(Patel et al., 2008).
Among the variables that were correlated with transplanted-
associated VO2Peak improvement at 1 year in the CAPER study
were cardiac variables (improved LV ejection fraction, maximum
heart rate) as well as corrected calcium level (Lim et al., 2020).
This latter finding of an association between calcium and change
in VO2Peak is intriguing given that disordered bone mineral
metabolism is a cardinal feature of the failing kidney, and
that calcium is centrally involved in regulating cardiac myocyte
contractility and relaxation (Hohendanner et al., 2013) and may
play a role in regulating myocardial function in uremia. The
study did not find a change in plasma corrected calcium levels
after kidney transplantation and further studies are needed to
explore this. Additionally, improvement in VO2Peak at 1 year
after transplantation in the CAPER study was also associated with
improvements in uremia and fluid overload that were already
notable at 2 months after transplantation. These results suggest
that reversal of cardiovascular molecular and ultrastructural
changes takes at least several months before an improvement
in cardiovascular function can be detected in kidney transplant
recipients. The pattern of cardiovascular functional changes
beyond 1 year after kidney transplantation is unknown and
further studies are warranted to evaluate this.
Chronic Kidney Disease (CKD)
Few studies have assessed cardiovascular functional capacity in
pre-dialytic CKD patients. In a study by Nelson et al. (2016)
the authors analyzed CPET data from 933 pre-operative patients
and found that 93/933 (9.97%) had CKD stage 3 (Nelson et al.,
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2016). The authors reported that patients with CKD stage 3 had
a significantly lower VO2Peak (mean difference 6%, 95% CI 1-
11%, p = 0.02), lower peak heart rate (mean difference 9 bpm,
95% CI 3–14%, p = 0.03) and impaired heart rate recovery (mean
difference 4 bpm, 95% CI 1–7, p < 0.001) compared to patients
with a GFR > 60. These findings are suggestive of subclinical
cardiovascular disease that can be objectively assessed in pre-
dialytic CKD patients. Given that microvascular dysfunction has
been shown to be involved in cardiovascular disease in CKD
and subclinical disease (Bajaj et al., 2020), further studies are
needed to determine whether CPET indices could be used as
a surrogate for assessing microvascular dysfunction in CKD.
To date, it is unknown how cardiovascular functional capacity
alters in the early stages of CKD or its natural history across
the spectrum of CKD severity. Additionally, further prospective
studies are desperately needed to link changes in VO2Peak with
cardiovascular outcomes in the CKD population. A summary of
observational studies and clinical trials that have utilized CPET-
derived endpoints in kidney patients is provided in Table 2.
POTENTIAL APPLICATIONS OF CPET
TECHNOLOGY IN NEPHROLOGY
CPET is currently widely used for risk stratification, clinical
evaluation and other applications in several medical specialities
outside of nephrology. The possibility of adopting global indices
such as VO2Peak in the field of nephrology has been made more
feasible due to technological advances in state-of-the-art CPET
and the prognostic value of submaximal indices. Here, we will
review several of its existing applications and discuss its potential
role in kidney patients.
Comprehensive Endpoints for
Cardio-Renal Trials
Given the limitations of current endpoints such as the LV
geometric indices discussed above for assessing cardiovascular
alterations in CKD, the potential to use comprehensive
endpoints such as VO2Peak for cardio-renal outcome
trials represents an incredibly attractive alternative. There
remains strong experimental and observational evidence
that adaptations of cardiovascular structure and function
can occur bidirectionally, that is, that adverse cardiovascular
remodeling can regress with the potential for recovery in
kidney patients (Melchor et al., 2002; Wali et al., 2005).
Because significant improvement in cardiovascular outcomes
has been reported after kidney transplantation (Pilmore
et al., 2010), these data suggest that cardiovascular change
in CKD is a modifiable process that can potentially be
controlled or halted. Moreover, these data call for sensitive
endpoints that can accurately track disease progression or
improvement. Considering the complex systemic and widespread
ultrastructural and molecular alterations that occur in CKD,
a comprehensive or aggregate endpoint such as VO2Peak,
that considers the complexity of cardiovascular and systemic
alterations, may therefore be a particularly appropriate index for
assessing cardiovascular improvement or decline in the setting
of shifting GFR.
The development of LV hypertrophy, and systolic and
diastolic dysfunction are well-recognized predictors of worse
cardiovascular outcomes in CKD patients (Charytan, 2014).
However, as previously noted above, imaging cardiac structure at
rest rather than under the stress of exercise, may be insufficiently
sensitive to detect impairment of the cardiovascular system due
to renal dysfunction, and may not reliably predict functional
performance (Ting et al., 2015). Imaging modalities such as
dobutamine stress echocardiography (DSE) have been used
in CKD patients. However, DSE has a reduced sensitivity
of 80% for detecting inducible ischemia in advanced CKD
patients (Parnham et al., 2014). This has been suggested to
be secondary to blunted chronotropic responses in CKD; LVH
with small intracavitary volume that can obscure detection
of wall motion abnormalities at stress, and microvascular
CAD that can be difficult to appreciate. Additionally, DSE
does not consider other organ system interactions that may
affect cardiovascular functional capacity in advancing CKD.
Furthermore, there is significant intrinsic value in improving
cardiovascular exercise capacity in patients (Malhotra et al.,
2016). A low VO2Peak defines functional aerobic impairment
or exercise intolerance, while an improvement in cardiovascular
exercise capacity is sensitively reflected by an increased
VO2Peak (Albouaini et al., 2007). A summary comparing risk
stratification methods, and their advantages and disadvantages
in CKD is provided in Table 3 (Hakeem et al., 2014;
Parnham et al., 2014).
From a regulatory standpoint, a significant advantage of
CPET-derived endpoints is that they have already been used
extensively in clinical trials in the general heart failure population
(Malhotra et al., 2016). Importantly, the US Food and Drug
Administration (FDA) has evaluated and approved new drugs
and devices that have utilized CPET-derived endpoints in clinical
trials (Malhotra et al., 2016).
Cardiovascular Risk Stratification and
Prognostic Utility
One of the main manifestations of heart failure is exercise
intolerance and this varies with severity of disease. Decreased
exercise capacity is associated with higher New York Heart
Association (NYHA) functional class, worse symptoms, poor
quality of life and decreased patient survival. Exercise capacity
is reduced even in mild heart failure and is reflective of an
inability of cardiac output to increase adequately with mild
exertion (Reddy et al., 1988). VO2Peak has been shown to
be strongly correlated with maximal cardiac output (Mitchell
et al., 1958; Ekblom and Hermansen, 1968). In heart failure, the
inability of cardiac output to appropriately increase may result
in insufficient perfusion of exercising muscles and premature
muscle fatigue (Harrington et al., 1997). Because the NYHA
classification of functional impairment in heart failure can be
inaccurate due to its subjective nature, objective assessment of
cardiovascular functional capacity by CPET offers a significant
advantage. Additionally, measures of cardiovascular functional
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TABLE 2 | Summary of clinical studies involving kidney patients that have utilized cardiopulmonary exercise testing (CPET) technology.
References Year Population Summary
Observational studies
Weaver et al. 2008 Pediatric patients: stage 2–4 CKD (n = 46),
renal transplant recipients (n = 33),
maintenance HD patients (n = 12) and
age-matched healthy controls (n = 33)
VO2max is decreased in children with CKD stages 3 to 4, those on
hemodialysis and transplant recipients. Lower VO2max can be predicted by the
presence of diastolic dysfunction, even if systolic function is normal.
Ting et al. 2013 N = 70 living donor kidney recipients. Reduced AT predicts critical care unit admission in patients undergoing kidney
transplantation.
De Souza Faria et al. 2013 N = 9 healthy adults, n = 29 pre-dialytic CKD
stages 3, 4, and 5.
VO2Peak as well as submaximal exercise tolerance was impaired in pre-dialytic
CKD patients.
Fassbinder et al. 2014 N = 54 patients with CKD, 27 stage 1 and 27
stage 2.
No statistically significant difference between stage 1 and 2 patients in
VO2Peak.
Ting et al. 2014 N = 240 patients waitlisted for kidney
transplantation, and followed for ≤ 5 years.
Patients with AT < 40% of predicted VO2Peak had significantly reduced 5-year
cumulative survival rate compared to those with ≥ 40%. Among the patients
with AT < 40%, those who underwent kidney transplantation had significantly
better survival compared with non-transplanted patients.
Ting et al. 2015 N = 80 patients with CKD (61 were dialysis
dependent) and 80 patients with essential
hypertension.
VO2Peak was significantly lower in patients in CKD patients compared to
hypertensive controls. Maladaptive LV changes and blunted chronotropic
responses were mechanistically involved in reduced cardiovascular functional
reserve.
Van Craenenbroeck et al. 2016 N = 63 CKD stages 1–5 and n = 18 healthy
controls.
Impaired VO2Peak in mild CKD (stages 1–3A) and correlated with eGFR. Pulse
wave velocity was one of the strongest independent determinants of VO2Peak.
Nelson et al. 2016 N = 993 pre-operative patients, that included
n = 93 CKD stage 3 patients.
Patients with CKD stage 3 had reduced VO2Peak.
Rogan et al. 2017 143 CKD stage 5 or 5d patients and 83
hypertensive controls.
CKD patients had reduced VO2Peak, and this was a significant independent
predictor of the physical component score (PCS) of the SF-36.
Kirkman et al. 2018 N = 31 stage 3–4 CKD and 21 matched healthy
controls.
VO2Peak, AT, maximum heart rate and 1-min heart rate recovery was reduced
in CKD stage 3 patients compared to healthy controls. CKD patients had
ventilation perfusion mismatching.
Clinical trials
Mustata et al. 2010 CKD patients, n = 10 randomized to 12 months
of exercise and n = 10 to standard of care.
Long-term exercise training improves VO2Peak, augmentation index and
health-related quality of life in patients with predialysis CKD.
McGregor et al. 2018 N = 46 hemodialysis patients randomized to
10 weeks intra-dialytic cycling, intra-dialytic
low-frequency electrical muscle stimulation
(LF-EMS) or non-exercise control
Ten weeks of intra-dialytic LF-EMS or cycling improved VO2Peak and muscular
strength.
HD, hemodialysis; AT, anaerobic threshold.
capacity obtained under incremental exercise load reflect overall
circulatory health and the ability to respond to physiological
and pathological cardio-circulatory stresses (Melchor et al., 2002;
Ting et al., 2014). Measures of resting central hemodynamics
do not correlate well with functional impairment. For these
reasons, CPET has become an integral tool for accurately
risk stratifying congestive heart failure patients for timely
heart transplantation worldwide (Mancini et al., 1991). The
identification of heart failure patients at high risk is crucial
to guide their management. In addition to providing robust
markers for cardiovascular functional capacity and exercise
intolerance, CPET permits assessment of the organ system
limiting gas exchange. This technology therefore has significant
advantages over 6 min walk tests (6MWT) for evaluating
exercise limitations.
Indices of cardiovascular functional capacity have
been independently associated with survival in multiple
settings. Mancini et al. (1991) in a landmark study
involving 114 ambulatory patients with heart failure
and reduced ejection fraction in the general population,
established VO2Peak ≤ 14 mL.min−1.kg−1 as a criterion
for which 1 year survival was significantly lower than
that achieved through transplantation. Individuals with a
VO2Peak > 14 mL.min−1.kg−1 had a 6% 1 year mortality and
this suggests that heart transplantation can be safely deferred in
this subgroup of symptomatic heart failure patients. VO2Peak
potently risk stratifies heart failure patients (with reduced
ejection fraction and preserved ejection fraction) into Weber
classes A, B, C, and D corresponding to VO2Peak > 20, 16–20,
10–16, <10 mL.min−1.kg−1 which associate with 3 years
transplant and mechanical circulatory support-free survival of
97, 93, 83, and 64% respectively (Ritt et al., 2015). Importantly,
in heart failure patients with reduced ejection fraction on beta-
blockers, VO2Peak retains its prognostic significance (O’Neill
et al., 2005), and is an important predictor of mortality in heart
failure with preserved ejection fraction (Haykowsky et al., 2011;
Dhakal et al., 2015). This latter finding is particularly relevant
to the renal population given that there is a disproportionate
increase in heart failure with preserved ejection compared with
reduced ejection fraction in CKD patients (Loutradis et al., 2018).
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TABLE 3 | Cardiovascular risk stratification methods in CKD.
Advantages Disadvantages
Serum biomarker assessment,
e.g., Troponin T
Easy to obtain; can sensitively detect myocardial necrosis; FDA
approved in patients with ESKD
Lack of specificity, elevated in more than one-third of
patients with ESKD, may require extended evaluation
Exercise stress EKG Widely used methodology for ruling in and ruling out CAD with
sensitivity ranging between 71 to 97% and specificity between
64 to 90%.
Requires some functional mobility; does not provide
measure of cardiovascular functional capacity; patients with
abnormal baseline EKG may limit standard testing
Resting echocardiography Widely available, easy to obtain, low cost; allows assessment of
LV geometry and ejection fraction
Inaccuracies with echo interpretation; significant volume
shifts occur in dialysis patients; most CKD patients have
diastolic failure (thereby limiting usefulness of ejection
fraction); LV geometric indices do not sensitivity track
disease progression in CKD
Exercise stress
echocardiography
Allows imaging of extent of regional wall motion responses to
stress; has better accuracy for detecting significant coronary
stenosis ranging from 80 to 90% compared to exercise EKG
Requires some functional mobility; does not provide
measure of cardiovascular functional capacity; technique
can be challenging
Dobutamine stress
echocardiography (DSE)
Well-validated and multiple studies have shown incremental
prognostic utility over clinical data for demonstrating resting and
stress-induced regional WMA
Increased LV mass or concentric remodeling limits
sensitivity for subtle WMA
Cardiac Magnetic Resonance
Imaging (CMR)
Can detect scar pattern and burden, presence of
subendocardial scar by delayed enhancement on CMR has
been associated with CAD risk factors, depressed LV ejection
fraction and severe CAD on angiography
Little data available on prognostic value of myocardial scar
pattern and burden using this technique in CKD population;
risk of gadolinium-induced nephrogenic systemic fibrosis
Myocardial perfusion
single-photon emission
computed tomography (MPS)
Well validated prognostic tool in CKD; high prevalence of
perfusion defects in ESKD patients
Presence of LVH can compromise sensitivity, due to partial
volume effect; can have false negative results in multi-vessel
disease due to balanced ischemia
Coronary artery calcium score
(CACS)
Coronary calcification is highly prevalent in CKD; offers
incremental predictive value to clinical risk factors
Does not sensitively track overall cardiovascular disease
progression or improvement
Cardiopulmonary Exercise
Testing (CPET)*
Comprehensive, takes into account alterations within the entire
oxygen transport chain in CKD; sub-maximal derived indices
can be obtained with relative ease and does not require
maximal volitional effort; can be coupled with imaging or
invasive techniques that can provide incremental
prognostic data
Selects for patients that have some functional mobility;
standardization of CPET testing is not yet uniform across
different CPET labs
*All risk stratification methods above except for CPET do not reflect overall functional ability and are reflective of only single-organ changes. CAD, Coronary artery disease;
LV, left ventricular; WMA, wall motion abnormality.
In addition to heart failure, VO2Peak has also been shown to be
a predictor of survival in chronic lung disease (Nixon et al., 1992;
Gitt et al., 2002; Oga et al., 2003; Arena and Sietsema, 2011) and
perioperative risk with major surgery (Older et al., 1999; Wilson
et al., 2010; Ting et al., 2013).
CPET-derived indices of cardiovascular functional
capacity have recently been shown to be robust predictors
of cardiovascular morbidity and premature death among
patients with advanced CKD, independent of LV measures (Ting
et al., 2013, 2014). In a landmark study by Ting et al. (2014) the
authors recruited 240 advanced CKD patients who underwent
CPET and were followed for ≤5 years. The authors reported
that patients with a VT < 40% of predicted peak VO2 had a
significantly reduced 5 years cumulative survival rate compared
with those that had VT ≥ 40% (P < 0.001). Significantly, among
the patients who had VT < 40%, those that underwent kidney
transplantation had a significantly better survival compared
with the non-transplanted patients. Among the patients with
VT ≥ 40%, survival did not differ significantly between those
who were transplanted and those who were not. These results
suggest that assessment of VT using CPET can provide a high
level of discrimination to risk stratify patients for timely kidney
transplantation, and that those with a VT < 40% may benefit
from early transplantation. These findings are critical given the
growing body of evidence that single surrogate markers from
the most established clinicopathologic factors, such as age and
LV mass index, have limited prognostic value for cardiovascular
outcomes in CKD.
Physiological Insights
A significant strength of CPET is that the technology
provides a wealth of data from a single assessment, including
hemodynamics, ventilatory efficiency, stability and O2 uptake
patterns and mechanical or musculoskeletal parameters. In
the general heart failure population, a number of indices have
been associated with important measures of cardiovascular
physiology such as circulatory power (an index of cardiac
systolic function), VE/VCO2 (an index of ventilatory efficiency
and pulmonary vascular resistance) and mean response time
(MRT, an index of right ventricular-pulmonary vascular
function during exercise) that can be easily attainable
using CPET non-invasively (Malhotra et al., 2016; Mezzani,
2017). CPET assessment, particularly when coupled with
hemodynamic, advanced imaging or invasive measures can
shed critical insight into the pathophysiology and determinants
of cardiovascular alterations, elucidate changes in specific
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Fick components and provide in-depth insight on the organ
limiting gas exchange.
CPET that is coupled with invasive hemodynamic assessment,
for example using radial or pulmonary arterial catheters enables
highly detailed patient phenotyping. This permits accurate
assessment of blood pressure and oxyhemoglobin measurement,
as well as simultaneous measurement of VO2 and arterial,
as well as mixed venous blood gasses during linear ramp
exercise. These data will allow Fick cardiac output derivation
and evaluation of the component variables of the Fick equation.
Patients with identical VO2Peak values with a diagnosis of heart
failure, may have significantly different levels of impairment
in the reserve capacity of each Fick variable (Malhotra et al.,
2016). No studies to date have comprehensively assessed CKD
patients using invasive CPET, or evaluated how the various Fick
variables alter as CKD progresses. By elucidating the mechanisms
of cardiovascular dysfunction during progressive CKD, new
therapeutic targets for improving cardiovascular outcomes in
CKD patients may be identified.
CONCLUSION AND FUTURE
DIRECTIONS
The significant public health need for better diagnostic and
therapeutic approaches to help improve cardiovascular outcomes
in CKD requires the implementation of effective, holistic
and forward-thinking strategies in our research efforts. Given
the multi-systemic nature of CVD development in CKD, an
integrative approach at all levels to study mechanisms of
disease, to track disease progression or improvement, for risk
stratification, and for implementation of appropriate clinical
trial endpoints maybe warranted. CPET provides a global test
of cardiovascular functional capacity that reflects the entire
oxygen transport system and may provide a potential solution
for an integrative approach to assessing the cardiovascular
system in CKD. The technology provides a wealth of data per
single assessment with mechanistic, physiological and prognostic
utility. Because a significant advantage of CPET is the ability
to couple the technology with other investigative modalities
such as invasive CPET and advanced imaging techniques, this
can provide comprehensive phenotyping and characterization
of multisystem changes that determine overall cardiovascular
functional capacity with a wide array of applications. While
CPET is a powerful technology, there are also important
limitations to the technology that warrants a brief discussion.
Firstly, CPET assessment does select for patients who retain
some functional ability and therefore, patients who are unable
to complete a cycle or treadmill test would be inherently
excluded from assessment; Secondly, like all types of exercise
testing, patients are required to present to a CPET lab and
tests must be conducted by a trained exercise physiologist or
clinician. Development of CPET technology has now enabled
measurement of ventilatory parameters using handheld devices
that can be used in an office-based setting, making the technology
increasingly more accessible.
Although CPET is a tool that is now widely available and
supported by sound scientific evidence in several clinical fields,
only a handful of studies have utilized CPET to study kidney
patients. Despite this, CPET has already provided a wealth
of hypothesis-generating data and has opened up many other
exciting questions in the cardio-renal field. The potential to
capitalize on next-generation CPET technology to help move the
cardio-renal field forward has provided strong rationale for the
urgent need for further CPET-related research in nephrology.
Here in the Division of Nephrology at Indiana University School
of Medicine, we have developed the first nephrology-based CPET
laboratory in the United States dedicated to studying kidney
patients. These efforts are in parallel with increasing interest
among nephrologists worldwide in exercise impairment and
musculoskeletal disorders in CKD patients. CPET technology
has the potential to drive actionable strategies in our collective
efforts to help reduce the burden of CVD in CKD. Strong efforts
to recognize these promising advances and to place them as a
primary research agenda in cardio-nephrology are needed.
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